NEW YORK, NY / ACCESS Newswire / August 14, 2025 / Pomerantz LLP is investigating claims on behalf of investors of LifeMD, Inc. ("LifeMD" or the "Company") (NASDAQ:LFMD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether LifeMD and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On August 5, 2025, LifeMD announced its second quarter 2025 results. Among other items, the Company revealed that higher customer acquisition costs pressured its business during the June quarter. Specifically, LifeMD spent 5% to 25% more to drive new customers to its RexMD platform- a telehealth platform focusing on men's health-in the second quarter compared to the first. In reacting to this announcement, a KeyBanc Capital Markets analyst stated that LifeMD "took its eye off the ball" in managing customer acquisition costs for RexMD amid its "enormous transition" in the quarter into the weight management space.

On this news, LifeMD's stock price fell $5.31 per share, or 44.84%, to close at $6.53 per share on August 6, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

SOURCE: Pomerantz LLP

View the original press release on ACCESS Newswire